L
LinkinVax
Operates as a clinical-stage biotechnology company
About LinkinVax
LinKinVax is a French biotechnology startup specializing in the rapid development of vaccines by integrating basic scientific research with industrial processes. The company operates in the biotechnology sector, focusing on creating highly versatile and efficient vaccines. LinKinVax serves pharmaceutical companies, healthcare providers, and research institutions looking for advanced vaccine solutions. The business model revolves around research and development (R&D) partnerships, clinical trials, and licensing agreements. Revenue is generated through collaboration fees, milestone payments, and royalties from licensed vaccines. The company is currently involved in a Phase I/IIa clinical study on HPV, showcasing its commitment to addressing critical healthcare needs.
Source: Dealroom company dataAt a glance
- Founded
- 2020
- Headquarters
- Paris, France
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Alain Tingaud- RDRémi Gaston- Dreyfus
- JKJean-Paul Kress
Giorgio Anania
Geoffrey M. Duyk, M.D., Ph.D.
Series A2 investors entered at this stage
In-Q-Tel
André-Jacques Auberton-Herve
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about LinkinVax on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See LinkinVax on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.